Induced Pluripotent Stem Cell (IPSC) Market Report 2025

The induced pluripotent stem cell (iPSC) market size has grown rapidly in recent years. It will grow from $3.3 billion in 2024 to $3.67 billion in 2025 at a compound annual growth rate (CAGR) of 11.3%. The growth in the historic period can be attributed to increasing healthcare expenditure, a rise in funding, rising awareness of stem cell products' medicinal potential, use of induced pluripotent stem cell (IPSC) based drug discovery, increasing demand for personalized medicine and cost-effective benefits of IPSC for drug discovery.

The induced pluripotent stem cell (iPSC) market size is expected to see strong growth in the next few years. It will grow to $5.29 billion in 2029 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to an increasing prevalence of chronic diseases, growth in genomic projects, development of IPSC-derived disease models, an increasing prevalence of genetic diseases, government initiatives and a rapid increase in technology. Major trends in the forecast period include development of pluripotent stem cells for Parkinson’s disease (PD), strategic collaborations and partnerships, development of induced pluripotent stem cell IPSC-derived nk cells, development of induced pluripotent stem cell (IPSC) for cell therapy, investment in regenerative medicine research and development, development of IPSC expansion medium, development of personalized IPSC and development of pluripotent stem cells for type I diabetes.

The induced pluripotent stem cell market is witnessing significant growth, driven primarily by the increasing prevalence of chronic disorders. Conditions such as heart disease, cancer, stroke, and diabetes find treatment avenues in induced pluripotent stem cells, which are obtained from any tissue source and genetically modified to emulate embryonic stem cells. According to a report by the Partnership to Fight Chronic Disorder (PFCD), 45% of the 133 million Americans surveyed had at least one chronic disorder. The report also estimates that 7 out of 10 deaths in the USA, approximately 1.7 million, result from chronic disorders, emphasizing the potential impact of induced pluripotent stem cell treatment. The rising incidence of chronic diseases is a key driver for the increasing demand in the induced pluripotent stem cell treatment market.

Contributing to the growth of the induced pluripotent stem cell market is the escalating prevalence of neurological disorders. These disorders, affecting the nervous system, encompass conditions such as acute spinal cord injury, Alzheimer's disease, and Amyotrophic Lateral Sclerosis (ALS). Pluripotent stem cells offer a valuable platform for studying disease mechanisms, conducting drug testing, and advancing regenerative therapies for neurological conditions such as Parkinson's and Alzheimer's disease. For instance, according to the Alzheimer's Association, an estimated 6.7 million Americans aged 65 and older will have Alzheimer's in 2023, with projections reaching 12.7 million by 2050. This upward trend in neurological disorders is a significant driver for the induced pluripotent stem cell market.

Companies are actively seeking strategic partnerships and collaborations to expand their geographic reach and enhance product portfolios. Bristol Myers Squibb and Century Therapeutics, in January 2022, joined forces to develop iPSC-derived allogenic cell therapies targeting acute myeloid leukemia and multiple myeloma. Similarly, Evotec and Sernova announced a strategic partnership in May 2022 to develop iPSC-based beta cell replacement therapy for treating type 1 and type 2 diabetes.

Major companies in the induced pluripotent stem cell (iPSC) market are collaborating to advance iPSC technology, aiming to enhance applications in regenerative medicine, improve disease modeling, accelerate drug discovery, and develop personalized therapeutic solutions. Induced pluripotent stem cell (iPSC) technology encompasses the scientific processes and methodologies used to reprogram adult somatic cells, such as skin or blood cells, back into a pluripotent state, allowing them to differentiate into any cell type in the body. For example, in April 2024, SCG Cell Therapy Pte Ltd, a Singapore-based biotechnology firm, teamed up with the Agency for Science, Technology and Research, a statutory board in Singapore, to establish joint laboratories focused on advancing cellular immunotherapies. This initiative, supported by nearly S$30 million, highlights Singapore's dedication to promoting biotechnology and healthcare solutions. The collaboration aims to create scalable manufacturing processes for GMP-grade iPSC products, addressing the challenges of translating laboratory innovations into clinically viable therapies.

In May 2024, Theragent Inc., a US-based biotechnology company, formed a partnership with Pluristyx Inc. This collaboration aims to expand Theragent's portfolio by leveraging Pluristyx's expertise in providing induced pluripotent stem cell (iPSC) products. Pluristyx Inc. is a US-based biotechnology company that specializes in iPSC products.

Major companies operating in the induced pluripotent stem cell (iPSC) market include FUJIFILM Holdings Corporation (FUJIFILM Cellular Dynamics, Inc), Thermo Fisher Scientific, Inc, Takara Bio, Inc, Lonza Group AG, Astellas Pharma Inc, ViaCyte, Inc, Ncardia, REPROCELL USA, Inc, Japan Tissue Engineering Co., Ltd, Merck KGaA, Cynata Therapeutics Limited, Dainippon Sumitomo Pharma, Shenzhen Bioscience, Shanghai Cell Therapy Group, Car-T Bio, JW therapeutics, Fosun Kite Biotechnology, Shanghai UniCar Therapy, Takaria Bio, SEED Biosciences SA, Cellerix, CellGenix, NsGene, TiGenix, Renuron Group, Smart Cells, Genenta Science, Biocad Rf, MSD, Pfizer, Roche, Pharmasyntez, Selvita, Mabion, Pure Biologics, OncoArendi Therapeutics, Proteon Pharmaceuticals, GlaxoSmithKline, Parexel, Bayer, Fate Therapeutics, Athersys, BrainStorm Cell Therapeutics, Cellular Biomedicine Group, Pluristem Therapeutics, Gamida Cell, VistaGen Therapeutics, Caladrius Biosciences, BioCanRx, CellCAN, CCRM, C3i, BioCells Argentina, Stem Cells, Royan Stem Cell Technology Co., Next BioSciences, CryoSave, BioHeart.

North America was the largest region in the induced pluripotent stem cell (IPSC) market in 2024. Western Europe was the second largest region in the global induced pluripotent stem cell (IPSC) market share. The regions covered in the induced pluripotent stem cell (IPSC) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the induced pluripotent stem cell (IPSC) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

Induced pluripotent stem cells are regenerated stem cells created from an existing adult cell, such as hepatocytes, fibroblasts, keratinocytes, or neurons. This process entails the introduction of specific genes that prompt the cell to become pluripotent, allowing it to differentiate into any cell type in the body, including heart, brain, and liver cells.

The principal derived cell types from induced pluripotent cells include hepatocytes, fibroblasts, keratinocytes, amniotic cells, and others. Hepatocytes, as the liver's primary functional cells, play a crucial role in an extensive range of metabolic, endocrine, and secretory functions. These cells find applications in various fields such as academic research, drug development and discovery, toxicity screening, and regenerative medicine, and are utilized in sectors including hospitals and research laboratories.

The induced pluripotent stem cell (iPSC) market research report is one of a series of new reports that provides induced pluripotent stem cell (iPSC) market statistics, including induced pluripotent stem cell (iPSC) industry global market size, regional shares, competitors with an induced pluripotent stem cell (iPSC) market share, detailed induced pluripotent stem cell (iPSC) market segments, market trends and opportunities, and any further data you may need to thrive in the induced pluripotent stem cell (iPSC) industry. This induced pluripotent stem cell (iPSC) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The induced pluripotent stem cell (iPSC) market consists of sales of induced pluripotent stem cells and related services. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.